Five days of oral topotecan (hycamtin®), a phase I and pharmacological study in adult patients with solid tumours

This publication has 15 references indexed in Scilit:

• Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor
  British Journal of Cancer, 1996
• Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors
  Investigational New Drugs, 1995
• Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
  Cancer Chemotherapy and Pharmacology, 1995
• A phase II study of topotecan administered intravenously as 5 daily infusions every 21 days to women with refractory epithelial ovarian carcinoma
  European Journal Of Cancer, 1993
• Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor
  JNCI Journal of the National Cancer Institute, 1993
• Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor
  Annals of Oncology, 1993
• Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity
  Journal of Medicinal Chemistry, 1991
• Regulation of the function of eukaryotic DNA topoisomerase I: topological conditions for inactivity.
  Proceedings of the National Academy of Sciences, 1989
• Eukaryotic DNA topoisomerase I reaction is topology dependent
  Nucleic Acids Research, 1988
• Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme.
  Proceedings of the National Academy of Sciences, 1976